

NDA 020164/S-101

SUPPLEMENT APPROVAL

Sanofi Aventis US LLC Attention: Gargi Lakhwani Manager, Global Regulatory Affairs 55 Corporate Drive Bridgewater, NJ 08807

Dear Ms. Lakhwani:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 12, 2013, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lovenox (enoxaparin sodium) injection.

We acknowledge receipt of your amendment dated November 15, 2013, which constituted a complete response to our October 11, 2013, action letter.

This "Changes Being Effected in 30 Days" supplemental new drug application provides for changes in carton and container labeling.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 020164/S-101.**" Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 020164/S-101 Page 2

If you have any questions, call Chelsea Bostic, Regulatory Business Process Manager, at (301) 796 - 8862.


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, PhD Chief, Branch I Division of Post-Marketing Activities I Office of Lifecycle Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosure(s):

Carton and Container Labeling



Digitally signed by Ramesh Raghavachari Date: 7/28/2023 02:23:23PM GUID: 502d0913000029f375128b0de8c50020